Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Review Article

Clinical Spectrum, Geographical Variability of COVID-19, and its Implications

Author(s): Md. Hasanul Banna Siam, Abdullah Al Mosabbir, Nahida Hannan Nishat, Ahsan Ahmed and Mohammad Sorowar Hossain*

Volume 2, Issue 5, 2021

Published on: 16 November, 2020

Article ID: e060521188078 Pages: 9

DOI: 10.2174/2666796701999201117103814

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has triggered a worldwide unprecedented public health crisis. Initially, COVID-19 was considered a disease of the respiratory system, as fever and at least one respiratory symptom was used to identify a suspected COVID-19 case. But there are now numerous reports of COVID-19 patients presenting with myriads of extrapulmonary symptoms, however, a substantial number of patients are asymptomatic. Additionally, there are significant clinical and epidemiological variations of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection across different geographical locations. The updated research, thus, challenges the existing surveillance system that is mainly based on fever and respiratory symptoms. As countries are coming out of lockdown to save economic fallout, a revised surveillance strategy is required to effectively identify and isolate the infected patients. Besides, since developing countries are becoming the new epicenters of pandemic and there are limited resources for RT-PCR based tests, documenting the clinical spectrum can play a vital role in the syndromic clinical diagnosis of COVID-19. A plethora of atypical symptoms also aids in guiding better treatment and remains as a source for further research. It is, therefore, crucial to understand the common and uncommon clinical manifestations of SARS-COV-2 infection and its variability across different geographic regions.

Keywords: COVID-19, clinical spectrum, geographic variation, pandemic, surveillance, asymptomatic.

Graphical Abstract
[1]
Worldometer. COVID-19 coronavirus pandemic Available from: https://www.worldometers.info/coronavirus/coronavirus-cases/#daily-cases
[2]
Gandhi M, Yokoe DS, Havlir DV. Asymptomatic transmission, the achilles’ heel of current strategies to control Covid-19. N Engl J Med 2020; 382(22): 2158-60.
[http://dx.doi.org/10.1056/NEJMe2009758] [PMID: 32329972]
[3]
Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020; 46(4): 586-90.
[http://dx.doi.org/10.1007/s00134-020-05985-9] [PMID: 32125455]
[4]
Li Y, Zhou W, Yang L, You R. Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor. Pharmacol Res 2020; 157: 104833.
[http://dx.doi.org/10.1016/j.phrs.2020.104833] [PMID: 32302706]
[5]
Zhang X, Tan Y, Ling Y, et al. Viral and host factors related to the clinical outcome of COVID-19. Nature 2020; 583(7816): 437-40.
[http://dx.doi.org/10.1038/s41586-020-2355-0] [PMID: 32434211]
[6]
Yu C, Lei Q, Li W, Wang X, Li W, Liu W. Epidemiological and clinical characteristics of 1663 hospitalized patients infected with COVID-19 in Wuhan, China: a single-center experience. J Infect Public Health 2020; 13(9): 1202-9.
[http://dx.doi.org/10.1016/j.jiph.2020.07.002] [PMID: 32718894]
[7]
Kuang Y, Zhang H, Zhou R, et al. Epidemiological and clinical characteristics of 944 cases of 2019 novel coronavirus infection of non-COVID-19 exporting city. Zhejiang, China. 2019. Available from: https://ssrn.com/abstract=3543604
[8]
Lechien JR, Chiesa-Estomba CM, Place S, et al. COVID-19 Task Force of YO-IFOS. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med 2020; 288(3): 335-44.
[http://dx.doi.org/10.1111/joim.13089] [PMID: 32352202]
[9]
Yuan J, Li M, Lv G, Lu ZK. Monitoring transmissibility and mortality of COVID-19 in Europe. Int J Infect Dis 2020; 95: 311-5.
[http://dx.doi.org/10.1016/j.ijid.2020.03.050] [PMID: 32234343]
[10]
Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020; 368: m1091.
[http://dx.doi.org/10.1136/bmj.m1091] [PMID: 32217556]
[11]
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA 2020; 323(13): 1239-42.
[http://dx.doi.org/10.1001/jama.2020.2648] [PMID: 32091533]
[12]
Global Health 50/50. Gender and sex are playing a crucial role in determining who is at risk of infection, severe illness and death from COVID-19 Available from: https://globalhealth5050.org/covid19/sex-disaggregated-data-tracker/
[13]
Global Health 50/50. COVID-19 sex-disaggregated data tracker Available from: https://globalhealth5050.org/the-sex-gender-and-covid-19-project/the-data-tracker/
[14]
Fu L, Wang B, Yuan T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. J Infect 2020; 80(6): 656-65.
[http://dx.doi.org/10.1016/j.jinf.2020.03.041] [PMID: 32283155]
[15]
Sun P, Qie S, Liu Z, Ren J, Li K, Xi J. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: A single arm meta-analysis. J Med Virol 2020; 92(6): 612-7.
[http://dx.doi.org/10.1002/jmv.25735] [PMID: 32108351]
[16]
CDC. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19) Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html
[17]
Guan WJ, Ni ZY, Hu Y, et al. China Medical Treatment Expert Group for Covid-19. China medical treatment expert group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382(18): 1708-20.
[http://dx.doi.org/10.1056/NEJMoa2002032] [PMID: 32109013]
[18]
Lamers MM, Beumer J, van der Vaart J, et al. SARS-CoV-2 productively infects human gut enterocytes. Science 2020; 369(6499): 50-4.
[http://dx.doi.org/10.1126/science.abc1669] [PMID: 32358202]
[19]
Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020; 75(7): 1730-41.
[http://dx.doi.org/10.1111/all.14238] [PMID: 32077115]
[20]
Pan L, Mu M, Yang P, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol 2020; 115(5): 766-73.
[http://dx.doi.org/10.14309/ajg.0000000000000620] [PMID: 32287140]
[21]
Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol 2020; 92(6): 552-5.
[http://dx.doi.org/10.1002/jmv.25728] [PMID: 32104915]
[22]
Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci 2020; 11(7): 995-8.
[http://dx.doi.org/10.1021/acschemneuro.0c00122] [PMID: 32167747]
[23]
Helms J, Kremer S, Merdji H, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med 2020; 382(23): 2268-70.
[http://dx.doi.org/10.1056/NEJMc2008597] [PMID: 32294339]
[24]
Wu Y, Xu X, Chen Z, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun 2020; 87: 18-22.
[http://dx.doi.org/10.1016/j.bbi.2020.03.031] [PMID: 32240762]
[25]
Mao L, Wang M, Chen S, et al. Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: A retrospective case series study. MedRxiv 2020.
[26]
Menni C, Valdes AM, Freidin MB, et al. Real-time tracking of self-reported symptoms to predict potential COVID-19. Nat Med 2020; 26(7): 1037-40.
[http://dx.doi.org/10.1038/s41591-020-0916-2] [PMID: 32393804]
[27]
Menni C, Sudre CH, Steves CJ, Ourselin S, Spector TD. Quantifying additional COVID-19 symptoms will save lives. Lancet 2020; 395(10241): e107-8.
[http://dx.doi.org/10.1016/S0140-6736(20)31281-2] [PMID: 32505221]
[28]
Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020; 77(6): 683-90.
[http://dx.doi.org/10.1001/jamaneurol.2020.1127] [PMID: 32275288]
[29]
Asadi-Pooya AA, Simani L. Central nervous system manifestations of COVID-19: A systematic review. J Neurol Sci 2020; 413: 116832.
[http://dx.doi.org/10.1016/j.jns.2020.116832] [PMID: 32299017]
[30]
Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19-associated acute hemorrhagic necrotizing encephalopathy: Imaging features. Radiology 2020; 296(2): E119-20.
[http://dx.doi.org/10.1148/radiol.2020201187] [PMID: 32228363]
[31]
Toscano G, Palmerini F, Ravaglia S, et al. Guillain-Barré syndrome associated with SARS-CoV-2. N Engl J Med 2020; 382(26): 2574-6.
[http://dx.doi.org/10.1056/NEJMc2009191] [PMID: 32302082]
[32]
Docherty AB, Harrison EM, Green CA, et al. Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO clinical characterisation protocol. MedRxiv 2020.
[33]
Zhou J, Sun J, Cao Z, et al. Epidemiological and clinical features of 201 COVID-19 patients in Changsha city, Hunan, China. Medicine (Baltimore) 2020; 99(34): e21824.
[http://dx.doi.org/10.1097/MD.0000000000021824] [PMID: 32846825]
[34]
Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet 2020; 395(10239): 1763-70.
[http://dx.doi.org/10.1016/S0140-6736(20)31189-2] [PMID: 32442528]
[35]
Wang S, Chen Z, Lin Y, et al. Epidemical and clinical characteristics of 165 patients infected with SARS-CoV-2 in Fujian Province. China. Available from: https://ssrn.com/abstract=3551402
[36]
Epic - Ist Super Di Sanità. Characteristics of SARS-CoV-2 patients dying in Italy-Report based on available data on 2020. Available from: https://www.epicentro.iss.it/en/coronavirus/bollettino/Report-COVID-2019_28_May_2020.pdf
[37]
COVID-19 national incident room surveillance team. COVID-19, Australia: Epidemiology Report 14 (Reporting week to 23:59 AEST 3 May 2020). Commun Dis Intell 2020; 44
[http://dx.doi.org/10.33321/cdi.2020.44.45]
[38]
Gov of Canada. COVID-19 daily epidemiology update Available from: https://health-infobase.canada.ca/covid-19/epidemiological-summary-covid-19-cases.html
[39]
Gudbjartsson DF, Helgason A, Jonsson H, et al. Spread of SARS-CoV-2 in the Icelandic Population. N Engl J Med 2020; 382(24): 2302-15.
[http://dx.doi.org/10.1056/NEJMoa2006100] [PMID: 32289214]
[40]
Passarelli PC, Lopez MA, Mastandrea Bonaviri GN, Garcia-Godoy F, D’Addona A. Taste and smell as chemosensory dysfunctions in COVID-19 infection. Am J Dent 2020; 33(3): 135-7.
[PMID: 32470238]
[41]
Richardson S, Hirsch JS, Narasimhan M, et al. the Northwell COVID-19 Research Consortium. The Northwell COVID-19 research consortium. Presenting characteristics, comorbidities, and outcomes among 5700 patients Hospitalized With COVID-19 in the New York city area. JAMA 2020; 323(20): 2052-9.
[http://dx.doi.org/10.1001/jama.2020.6775] [PMID: 32320003]
[42]
Ho JS, Tambyah PA, Ho AF, Chan MY, Sia C-H. Effect of coronavirus infection on the human heart: A scoping review. Eur J Prev Cardiol 2020; 27(11): 1136-48.
[http://dx.doi.org/10.1177/2047487320925965] [PMID: 32423250]
[43]
Kochi AN, Tagliari AP, Forleo GB, Fassini GM, Tondo C. Cardiac and arrhythmic complications in patients with COVID-19. J Cardiovasc Electrophysiol 2020; 31(5): 1003-8.
[http://dx.doi.org/10.1111/jce.14479] [PMID: 32270559]
[44]
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229): 1054-62.
[http://dx.doi.org/10.1016/S0140-6736(20)30566-3] [PMID: 32171076]
[45]
Peng YD, Meng K, Guan HQ, et al. [Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV]. Zhonghua Xin Xue Guan Bing Za Zhi 2020; 48(6): 450-5.
[http://dx.doi.org/10.3760/cma.j.cn112148-20200220-00105] [PMID: 32120458]
[46]
Kim I-C, Kim JY, Kim HA, Han S. COVID-19-related myocarditis in a 21-year-old female patient. Eur Heart J 2020; 41(19): 1859.
[http://dx.doi.org/10.1093/eurheartj/ehaa288] [PMID: 32282027]
[47]
Solano-López J, Sánchez-Recalde A, Zamorano JL. SARS-CoV-2, a novel virus with an unusual cardiac feature: inverted takotsubo syndrome. Eur Heart J 2020; 41(32): 3106.
[http://dx.doi.org/10.1093/eurheartj/ehaa390] [PMID: 32391885]
[48]
Azarkish M, Laleh Far V, Eslami M, Mollazadeh R. Transient complete heart block in a patient with critical COVID-19. Eur Heart J 2020; 41(22): 2131.
[http://dx.doi.org/10.1093/eurheartj/ehaa307] [PMID: 32285920]
[49]
Alramthan A, Aldaraji W. Two cases of COVID-19 presenting with a clinical picture resembling chilblains: first report from the Middle East. Clin Exp Dermatol 2020; 45(6): 746-8.
[http://dx.doi.org/10.1111/ced.14243] [PMID: 32302422]
[50]
Galván Casas C, Català A, Carretero Hernández G, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol 2020; 183(1): 71-7.
[http://dx.doi.org/10.1111/bjd.19163] [PMID: 32348545]
[51]
Sachdeva M, Gianotti R, Shah M, et al. Cutaneous manifestations of COVID-19: Report of three cases and a review of literature. J Dermatol Sci 2020; 98(2): 75-81.
[http://dx.doi.org/10.1016/j.jdermsci.2020.04.011] [PMID: 32381430]
[52]
Wu P, Duan F, Luo C, et al. Characteristics of ocular findings of patients with Coronavirus disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol 2020; 138(5): 575-8.
[http://dx.doi.org/10.1001/jamaophthalmol.2020.1291] [PMID: 32232433]
[53]
Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 2020; 97(5): 829-38.
[http://dx.doi.org/10.1016/j.kint.2020.03.005] [PMID: 32247631]
[54]
Hirsch JS, Ng JH, Ross DW, et al. Northwell COVID-19 Research Consortium; Northwell Nephrology COVID-19 Research Consortium. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int 2020; 98(1): 209-18.
[http://dx.doi.org/10.1016/j.kint.2020.05.006] [PMID: 32416116]
[55]
Nasr SH, Kopp JB. COVID-19-associated collapsing glomerulopathy: an emerging entity. Kidney Int Rep 2020; 5(6): 759-61.
[http://dx.doi.org/10.1016/j.ekir.2020.04.030] [PMID: 32368701]
[56]
Souza WM de, Buss LF, et al. Epidemiological and clinical characteristics of the early phase of the COVID-19 epidemic in Brazil. MedRxiv 2020.
[57]
Shi S, Qin M, Cai Y, et al. Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. Eur Heart J 2020; 41(22): 2070-9.
[http://dx.doi.org/10.1093/eurheartj/ehaa408] [PMID: 32391877]
[58]
Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 2020; 5(7): 802-10.
[http://dx.doi.org/10.1001/jamacardio.2020.0950] [PMID: 32211816]
[59]
Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020; 17(5): 259-60.
[http://dx.doi.org/10.1038/s41569-020-0360-5] [PMID: 32139904]
[60]
Ronco C, Reis T, Husain-Syed F. Management of acute kidney injury in patients with COVID-19. Lancet Respir Med 2020; 8(7): 738-42.
[http://dx.doi.org/10.1016/S2213-2600(20)30229-0] [PMID: 32416769]
[61]
Xia J, Tong J, Liu M, Shen Y, Guo D. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. J Med Virol 2020; 92(6): 589-94.
[http://dx.doi.org/10.1002/jmv.25725] [PMID: 32100876]
[62]
Daruich A, Martin D, Bremond-Gignac D. Ocular manifestation as first sign of Coronavirus Disease 2019 (COVID-19): Interest of telemedicine during the pandemic context. J Fr Ophtalmol 2020; 43(5): 389-91.
[http://dx.doi.org/10.1016/j.jfo.2020.04.002] [PMID: 32334847]
[63]
Joob B, Wiwanitkit V. COVID-19 can present with a rash and be mistaken for dengue. J Am Acad Dermatol 2020; 82(5): e177.
[http://dx.doi.org/10.1016/j.jaad.2020.03.036] [PMID: 32213305]
[64]
Manalo IF, Smith MK, Cheeley J, Jacobs R. A dermatologic manifestation of COVID-19: Transient livedo reticularis. J Am Acad Dermatol 2020; 83(2): 700.
[http://dx.doi.org/10.1016/j.jaad.2020.04.018] [PMID: 32283229]
[65]
Wang Y, Liu Y, Liu L, Wang X, Luo N, Li L. Clinical outcomes in 55 Patients with severe acute respiratory syndrome coronavirus 2 Who were asymptomatic at hospital admission in Shenzhen, China. J Infect Dis 2020; 221(11): 1770-4.
[http://dx.doi.org/10.1093/infdis/jiaa119] [PMID: 32179910]
[66]
Pan X, Chen D, Xia Y, et al. Asymptomatic cases in a family cluster with SARS-CoV-2 infection. Lancet Infect Dis 2020; 20(4): 410-1.
[http://dx.doi.org/10.1016/S1473-3099(20)30114-6] [PMID: 32087116]
[67]
Day M. Covid-19: four fifths of cases are asymptomatic, China figures indicate. BMJ 2020; 369: m1375.
[http://dx.doi.org/10.1136/bmj.m1375] [PMID: 32241884]
[68]
Jeng MJ. Coronavirus disease 2019 in children: Current status. J Chin Med Assoc 2020; 83(6): 527-33.
[http://dx.doi.org/10.1097/JCMA.0000000000000323] [PMID: 32502117]
[69]
Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill 2020; 25(10): 2000180.
[http://dx.doi.org/10.2807/1560-7917.ES.2020.25.10.2000180] [PMID: 32183930]
[70]
Nishiura H, Kobayashi T, Miyama T, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis 2020; 94: 154-5.
[http://dx.doi.org/10.1016/j.ijid.2020.03.020] [PMID: 32179137]
[71]
CDC. COVID-19 pandemic planning scenarios Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html
[72]
Reuters. Tracking the spread of the novel coronavirus Available from: https://graphics.reuters.com/CHINA-HEALTH-MAP/0100B59S39E/index.html
[73]
Bendavid E, Mulaney B, Sood N, et al. COVID-19 antibody seroprevalence in Santa Clara County, California. Int J Epidemiol 2021; 1: 1-0.
[http://dx.doi.org/10.1093/ije/dyab010] [PMID: 33615345]
[74]
Mallapaty S. Antibody tests suggest that coronavirus infections vastly exceed official counts. Nature 2020.
[http://dx.doi.org/10.1038/d41586-020-01095-0] [PMID: 32303734]
[75]
Jin J-M, Bai P, He W, et al. Gender differences in patients with COVID-19: Focus on severity and mortality. Front Public Health 2020; 8: 152.
[http://dx.doi.org/10.3389/fpubh.2020.00152] [PMID: 32411652]
[76]
Lippi G, Mattiuzzi C, Sanchis-Gomar F, Henry BM. Clinical and demographic characteristics of patients dying from COVID-19 in Italy vs China. J Med Virol 2020; 92(10): 1759-60.
[http://dx.doi.org/10.1002/jmv.25860] [PMID: 32275075]
[77]
Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; 8(5): 475-81.
[http://dx.doi.org/10.1016/S2213-2600(20)30079-5] [PMID: 32105632]
[78]
Lu X, Zhang L, Du H, et al. Chinese Pediatric Novel Coronavirus Study Team. Chinese pediatric novel coronavirus study team. SARS-CoV-2 infection in children. N Engl J Med 2020; 382(17): 1663-5.
[http://dx.doi.org/10.1056/NEJMc2005073] [PMID: 32187458]
[79]
Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China. Pediatrics 2020; 145(6): e20200702.
[http://dx.doi.org/10.1542/peds.2020-0702] [PMID: 32179660]
[80]
Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr 2020; 109(6): 1088-95.
[http://dx.doi.org/10.1111/apa.15270] [PMID: 32202343]
[81]
Aylward Bruce. Report of the WHO-China joint mission on coronavirus disease. 2019. Available from: https://digitallibrary.un.org/record/3859867?ln=en
[82]
Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet 2020; 395(10226): 809-15.
[http://dx.doi.org/10.1016/S0140-6736(20)30360-3] [PMID: 32151335]
[83]
Forster P, Forster L, Renfrew C, Forster M. Phylogenetic network analysis of SARS-CoV-2 genomes. Proc Natl Acad Sci USA 2020; 117(17): 9241-3.
[http://dx.doi.org/10.1073/pnas.2004999117] [PMID: 32269081]
[84]
Cao Y, Li L, Feng Z, et al. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discov 2020; 6: 11.
[http://dx.doi.org/10.1038/s41421-020-0147-1]
[85]
Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ 2020; 368: m606.
[http://dx.doi.org/10.1136/bmj.m606] [PMID: 32075786]
[86]
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223): 507-13.
[http://dx.doi.org/10.1016/S0140-6736(20)30211-7] [PMID: 32007143]
[87]
Zhu J, Ji P, Pang J, et al. Clinical characteristics of 3062 COVID-19 patients: A meta-analysis. J Med Virol 2020; 92(10): 1902-14.
[http://dx.doi.org/10.1002/jmv.25884] [PMID: 32293716]
[88]
Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol 2020; 277(8): 2251-61.
[http://dx.doi.org/10.1007/s00405-020-05965-1] [PMID: 32253535]
[89]
Jang Y, Son HJ, Lee S, Lee EJ, Kim TH, Park SY. Olfactory and taste disorder: The first and only sign in a patient with SARS-CoV-2 pneumonia. Infect Control Hosp Epidemiol 2020; 41(9): 1103.
[http://dx.doi.org/10.1017/ice.2020.151] [PMID: 32307026]
[90]
Moein ST, Hashemian SMR, Mansourafshar B, Khorram-Tousi A, Tabarsi P, Doty RL. Smell dysfunction: a biomarker for COVID-19. Int Forum Allergy Rhinol 2020; 10(8): 944-50.
[http://dx.doi.org/10.1002/alr.22587] [PMID: 32301284]
[91]
Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol 2020; 34(5): e212-3.
[http://dx.doi.org/10.1111/jdv.16387] [PMID: 32215952]
[92]
Qasim M, Yasir M, Ahmad W, et al. Early epidemiological and clinical manifestations of COVID-19 in Japan. MedRxiv 2020.
[93]
Casas Rojo JM, Antón Santos JM, Millán Núñez-Cortés J, et al. Clinical characteristics of patients hospitalized with COVID-19 in Spain: Results from the SEMI-COVID-19 Network. MedRxiv 2020.
[94]
Karadag E. Increase in COVID-19 cases and case-fatality and case-recovery rates in Europe: A cross-temporal meta-analysis. J Med Virol 2020; 92(9): 1511-7.
[http://dx.doi.org/10.1002/jmv.26035] [PMID: 32437052]
[95]
Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 2020; 323(18): 1775-6.
[http://dx.doi.org/10.1001/jama.2020.4683] [PMID: 32203977]
[96]
World News- Mirror. WHO chief warns Europe must prepare for 2nd more deadly coronavirus wave this winter Available from: https://www.mirror.co.uk/news/world-news/who-medic-warns-drop-deaths-22042662
[97]
Liang W, Feng Z, Rao S, et al. Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus. Gut 2020; 69(6): 1141-3.
[http://dx.doi.org/10.1136/gutjnl-2020-320832] [PMID: 32102928]
[98]
Moitra P, Alafeef M, Dighe K, Frieman MB, Pan D. Selective naked-eye detection of SARS-CoV-2 mediated by N gene targeted antisense oligonucleotide capped plasmonic nanoparticles. ACS Nano 2020; 14(6): 7617-27.
[http://dx.doi.org/10.1021/acsnano.0c03822] [PMID: 32437124]

© 2022 Bentham Science Publishers | Privacy Policy